Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Recent trial failures highlight challenges in clinical development for head and neck cancer, says GlobalData

AstraZeneca/Medimmune Therapeutics’ Imfinzi (durvalumab), an immunotherapy targeting programmed death-ligand 1 (PD-L1), recently failed to demonstrate increased overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in its Phase III KESTREL clinical trial (NCT02551159). This recent failure highlights the challenges in trial completions and development of novel entities in […]
Read more

AbbVie pips Gilead to dominate Japan’s hepatitis C virus digital marketing space, says GlobalData

The hepatitis C virus (HCV) therapeutics market in Japan is highly competitive with stiff competition between Gilead and AbbVie. However, AbbVie has taken an edge over Gilead in terms of HCV-related digital initiatives, finds GlobalData, a leading data and analytics company. According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of HCV […]
Read more

COVID-19 booster shots becoming more likely as variants could reduce effectiveness of vaccines

If new SARS-CoV-2 variants continue to develop, they could affect not only the effectiveness of COVID-19 vaccines, but also the natural immunity that COVID-19 survivors have developed – making annual booster shots required for COVID-19 immunity, says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “Of the several natural variants […]
Read more

MANTA and MANTA-RAy safety readouts boost Jyseleca’s prospects in the US

Following Galapagos’ announcement of pooled interim results from its ongoing MANTA and MANTA-RAy safety studies for Jyseleca (filgotinib); Rose Joachim, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Interim data from MANTA and MANTA-RAy should ease fears that Jyseleca may negatively impact sperm health in men with inflammatory bowel disease […]
Read more

Immunotherapy for microsatellite stable colorectal cancer holds promise

During Colorectal Cancer Awareness month, it is important to highlight that precision medicine approaches are gaining traction in this indication. Positive results from any of the ongoing late-stage trials in microsatellite stable (MSS) colorectal cancer patients could see immunotherapy gaining a foothold in this indication, says GlobalData, a leading data and analytics company. Jessica McCormack, […]
Read more

COVID-19 has accelerated digital transformation timeline for pharmaceutical industry

Even though the pharmaceutical sector used to display a more conservative stance toward the adoption of new technologies, the COVID-19 pandemic acted as a trigger that forced the pharmaceutical sector to accelerate the digital transformation timeline, says GlobalData, a leading data and analytics company. According to a GlobalData survey, 35% of pharmaceutical industry professionals believe […]
Read more

COVID-19 pandemic continues to significantly impact clinical research

With the COVID-19 pandemic recently passing one year in duration, clinical research continues to be significantly affected. Sponsors have had to modify trial designs to prevent the suspension, termination, or withdrawal of planned and ongoing clinical trials. The adaptation and usage of decentralized trials and virtual technologies have been strongly accelerated in order to mitigate […]
Read more

Launch of generic brands for expensive oncology drugs improves treatment affordability and access in India, says GlobalData

The Central Drugs Standard Control Organization (CDSCO) has recently approved several generic versions of sunitinib to treat kidney cancer. Against this backdrop, the approval of generic brands of expensive oncology drugs will not only help in reducing the cost of these life-saving drugs but also improve access and adherence to treatment in the future, says […]
Read more

New standard of care in hepatocellular carcinoma shifts the treatment paradigm to a grey area, says GlobalData

The approval of Roche’s Avastin (bevacizumab) plus Tecentriq (atezolizumab), in addition to the long list of pipeline products, opens up gaps in the treatment paradigm regarding the sequence of treatments, says GlobalData, a leading data and analytics company. Mandana Emamzadeh, PhD, Pharma Analyst at GlobalData, comments, “The hepatocellular carcinoma (HCC) market is evolving swiftly after […]
Read more

The COVID-19 pandemic is driving an increase in novel FDA approvals and outsourcing of manufacturing

Innovative drug approvals increased in the US between 2019 and 2020. This increase happened despite the FDA’s stretched resources, as it had to reassign staff to cope with COVID-19-related activities. The agency approved 121 novel drugs in 2020, compared with 119 in in 2019, says GlobalData, a leading data and analytics company. Adam Bradbury, PharmSource Analyst at GlobalData comments: “There was a large increase in approvals of new molecular entities (NMEs), the most innovative drug type with 21% more NME approvals than in 2019. There were also more small cap pharma–sponsored drug approvals and overall approvals compared […]
Read more

COVID-19 disruption of clinical trials varies by therapy area

The number of clinical trials disrupted by the COVID-19 pandemic continues to increase into 2021, although the degree of disruption varies depending on the therapy area, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, MPH, Senior Analyst at GlobalData, comments: “Companies and organizations continue to report trial disruptions due to the COVID-19 pandemic, including delayed initiation, delayed enrollment, and slow enrollment, although not all therapy areas have been equally affected.” Comparing April 2020 […]
Read more
1 … 67 68 69 70 71 … 108